Search results for "VIROLOGY"

showing 10 items of 2354 documents

Molecular Surveillance of HIV-1 in Madrid, Spain: a Phylogeographic Analysis ▿

2011

ABSTRACT The molecular epidemiology of HIV-1 is constantly changing, mainly as a result of human migratory flows and the high adaptive ability of the virus. In recent years, Spain has become one of Europe's main destinations for immigrants and one of the western European countries with the highest rates of HIV-positive patients. Using a phylogeographic approach, we have analyzed the relationship between HIV-1 variants detected in immigrant and native populations of the urban area of Madrid. Our project was based on two coincidental facts. First, resistance tests were extended to naïve and newly diagnosed patients, and second, the Spanish government legislated the provision of legal status t…

medicine.medical_specialtyGenotypemedia_common.quotation_subjectImmunologyImmigrationMolecular Sequence DataHuman immunodeficiency virus (HIV)HIV InfectionsBiologyDestinationsmedicine.disease_causeMicrobiologylaw.invention03 medical and health sciences0302 clinical medicinePopulation GroupslawVirologyEpidemiologymedicinePrevalenceCluster AnalysisHumans030212 general & internal medicine030304 developmental biologymedia_commonTransients and Migrants0303 health sciencesMolecular EpidemiologyMolecular epidemiologySequence Analysis DNA3. Good healthPhylogeographyPhylogeographyTransmission (mechanics)Genetic Diversity and EvolutionSpainpol Gene Products Human Immunodeficiency VirusInsect ScienceCohortHIV-1Demography
researchProduct

Sequential evolution of genotype GII.4 norovirus variants causing gastroenteritis outbreaks from 2001 to 2006 in Eastern Spain.

2008

Noroviruses are the most common cause of outbreaks of viral gastroenteritis worldwide. Norovirus outbreaks were surveyed in Catalonia and the region of Valencia (Eastern Spain) between January 2001 and December 2006 as part of the European Union funded network "Food-borne viruses in Europe". During this time the etiology and epidemiological features of 194 outbreaks of acute non-bacterial gastroenteritis were investigated and norovirus was identified as causing 169 (87.1%) of them. Molecular epidemiology of viral strains was studied by RT-PCR and sequencing part of the RNA polymerase gene in ORF1 from 153 outbreak strains. The most commonly identified norovirus genotype was GII.4 (71.9% of …

medicine.medical_specialtyGenotypevirusesBiologymedicine.disease_causeMicrobiologyDisease OutbreaksEvolution MolecularFecesfluids and secretionsVirologyGenotypeGenetic variationEpidemiologymedicinemedia_common.cataloged_instanceHumansEuropean unionPhylogenymedia_commonCaliciviridae InfectionsMolecular epidemiologyNorovirusvirus diseasesOutbreakGenetic VariationVirologyGastroenteritisInfectious DiseasesSpainNorovirusEtiologySeasonsJournal of medical virology
researchProduct

Antibody Pattern of HCV Infection and Hepatocellular Carcinoma in Italy: A Case Control Study

1994

The association of hepatitis C virus (HCV) infection with hepatocellular carcinoma (HCC) and the presence of a specific antibody pattern was assessed by means of a case-control study conducted in Italy on 65 consecutive newly diagnosed HCC cases and 99 sex- and age-matched control patients with chronic nonhepatic disease. The prevalences of antibody to HCV (anti-HCV) and hepatitis B surface antigen (HBsAg) observed were 66.2% and 24.6%, respectively. The relative risk for the association of each of the two markers with HCC, as calculated by multiple logistic analysis, was 26.9 (95% confidence intervals (CI): 9.9–72.5) for anti-HCV and 11.4 (95% CI: 3.1–41.1) for HBsAg. Thus, they constitute…

medicine.medical_specialtyHBsAgbiologybusiness.industryHepatitis C virusCase-control studyDiseasemedicine.disease_causemedicine.diseaseGastroenterologyVirologydigestive system diseasesConfidence intervalInternal medicineHepatocellular carcinomaRelative riskmedicinebiology.proteinAntibodybusiness
researchProduct

Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients

2015

The aim of this review was to detail the current therapies and treatments for chronic hepatitis C virus in coinfected patients, focusing on HCV antiviral agents currently used in practice today or scheduled to enter the open market soon. Several direct-acting antiviral (DAA) combinations show high sustained virologic response (SVR) rates in HIV/HCV-coinfected patients, which are often close to those observed in HCV-monoinfected patients. Most recommendations regarding treatment stem from trials with coinfected patients. However, data are lacking for some aspects of HCV-treatment in coinfection, so extrapolations must be made from data obtained predominately from monoinfected patients. HIV/H…

medicine.medical_specialtyHepatitis C virusImmunologyPopulationHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeAntiviral AgentsVirusLiver diseaseChronic hepatitisVirologyInternal medicinemedicineHumansHiv infected patientsDrug Interactionseducationeducation.field_of_studyOncology (nursing)business.industryvirus diseasesHematologyHepatitis C Chronicmedicine.diseasedigestive system diseasesTreatment OutcomeInfectious DiseasesOncologyImmunologyCoinfectionDrug Therapy CombinationbusinessCurrent Opinion in HIV and AIDS
researchProduct

Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVIH cohort

2017

BACKGROUND AND AIMS: Few data exist on changes to substance use patterns before and after hepatitis C virus (HCV) treatment. We used longitudinal data of HIV-HCV co-infected individuals to examine whether receiving pegylated interferon (Peg-IFN)-based therapy irrespective of HCV clearance could modify tobacco, cannabis and alcohol use. DESIGN: A prospective cohort of HIV-HCV co-infected individuals was enrolled from 2006. Participants' clinical data were retrieved from medical records and socio-demographic and behavioural characteristics were collected by yearly self-administered questionnaires. SETTING: Data were collected across 17 hospitals in France. PARTICIPANTS: All HIV-HCV co-infecte…

medicine.medical_specialtyHepatitis C virusMedicine (miscellaneous)Binge drinkingmedicine.disease_causeUnit of alcohol03 medical and health sciences0302 clinical medicinePegylated interferonInternal medicinemedicine030212 general & internal medicineProspective cohort studybiologybusiness.industryvirus diseasesHepatitis Cmedicine.diseasebiology.organism_classificationVirologydigestive system diseases3. Good healthPsychiatry and Mental healthCohort030211 gastroenterology & hepatologyCannabisbusinessmedicine.drugAddiction
researchProduct

Patient-to-patient transmission of hepatitis C virus (HCV) during colonoscopy diagnosis

2010

Abstract Background No recognized risk factors can be identified in 10-40% of hepatitis C virus (HCV)-infected patients suggesting that the modes of transmission involved could be underestimated or unidentified. Invasive diagnostic procedures, such as endoscopy, have been considered as a potential HCV transmission route; although the actual extent of transmission in endoscopy procedures remains controversial. Most reported HCV outbreaks related to nosocomial acquisition have been attributed to unsafe injection practices and use of multi-dose vials. Only a few cases of likely patient-to-patient HCV transmission via a contaminated colonoscope have been reported to date. Nosocomial HCV infecti…

medicine.medical_specialtyHepatitis C virusMolecular Sequence DataColonoscopyHepacivirusViral Nonstructural Proteinsmedicine.disease_causelcsh:Infectious and parasitic diseaseschemistry.chemical_compoundVirologyEpidemiologyDisease Transmission InfectiousmedicineHumanslcsh:RC109-216NS5BRetrospective StudiesCross InfectionMolecular Epidemiologymedicine.diagnostic_testbusiness.industryTransmission (medicine)ResearchOutbreakRetrospective cohort studyColonoscopySequence Analysis DNAHepatitis Cmedicine.diseaseHepatitis CVirologyInfectious DiseaseschemistryRNA ViralbusinessVirology Journal
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C

2012

Summary.  Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naive patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400  mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44…

medicine.medical_specialtyHepatitis C virusPopulationmacromolecular substancesmedicine.disease_causeGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawVirologyInternal medicineMedicineeducationeducation.field_of_studyHepatologybusiness.industryRibavirintechnology industry and agriculturevirus diseasesmedicine.diseasedigestive system diseasesMenopauseInfectious DiseasesEndocrinologychemistryPropensity score matchingSteatosisMetabolic syndromebusinessJournal of Viral Hepatitis
researchProduct

Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study

2004

Summary Background : In patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels, liver fibrosis has been reported in 0–22% of cases and advanced liver disease in 5–10% of cases. Aim : To determine whether patients with persistently normal alanine aminotransferase levels clear infection after anti-viral therapy at equal or different rates from infected patients with raised alanine aminotransferase levels. Methods : Thirty-five hepatitis C virus RNA-positive patients with fibrosis at liver histology (Group 1) were matched for genotype, sex, age and histology with patients with raised alanine aminotransferase levels (Group 2). Both groups were …

medicine.medical_specialtyHepatologyCombination therapybiologybusiness.industryRibavirinHepatitis C virusGastroenterologyOdds ratiomedicine.disease_causemedicine.diseaseVirologyGastroenterologyConfidence intervalchemistry.chemical_compoundLiver diseaseAlanine transaminasechemistryFibrosisInternal medicinebiology.proteinmedicinePharmacology (medical)businessAlimentary Pharmacology & Therapeutics
researchProduct

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin

2012

Summary.  It is unclear whether the current threshold for ‘high’ hepatitis C virus (HCV) RNA level (800 000 IU/mL) is optimal for predicting sustained virological response (SVR). We retrospectively analysed pretreatment HCV RNA levels and SVR rates in 1529 mono-infected and 176 HIV–HCV co-infected patients treated with peginterferon alfa-2a (40 kD) plus ribavirin. We improved the threshold for differentiating low and high viral load by fitting semiparametric generalized additive logistic regression models to the data and constructing receiver operating characteristics curves. Among HCV genotype 1 mono-infected patients, the difference in SVR rates between those with low and high baseline HC…

medicine.medical_specialtyHepatologyReceiver operating characteristicbusiness.industryRibavirinHepatitis C virusvirus diseasesHepatitis Cmedicine.diseaseLogistic regressionmedicine.disease_causeGastroenterologydigestive system diseaseschemistry.chemical_compoundInfectious DiseaseschemistryVirologyInternal medicineGenotypeImmunologymedicinebusinessViral loadPeginterferon alfa-2amedicine.drugJournal of Viral Hepatitis
researchProduct

High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C

2012

Soluble CD36 (sCD36) plasma levels, a known marker of cardiometabolic disorders, are associated with surrogate markers of steatosis, while experimental and human studies show a link between CD36 expression in the liver and steatosis. In a cohort of patients with genotype 1 chronic hepatitis C (G1 CHC), we tested the association of sCD36 plasma levels with host and viral factors and sustained virological response (SVR). One hundred and seventy-five consecutive biopsy-proven patients were studied. sCD36 plasma levels were assessed by an in-house ELISA. All biopsies were scored by one pathologist for staging and grading (Scheuer) and graded for steatosis, which was considered moderate-severe i…

medicine.medical_specialtyHepatologySurrogate endpointbusiness.industryRibavirinFatty liverHepatitis Cmedicine.diseaseGastroenterologychemistry.chemical_compoundInfectious DiseasesInsulin resistancechemistryPegylated interferonVirologyInternal medicineImmunologySeverity of illnessmedicineSteatosisbusinessmedicine.drugJournal of Viral Hepatitis
researchProduct